UBS analyst Joshua Spector downgraded Pactiv Evergreen (PTVE) to Neutral from Buy with an $18 price target The firm expects Q4 earnings for North America Chemicals and Packaging to be challenging, but with the sector on average down 10% over the last month, this negativity may already be priced in, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTVE:
- Pactiv Evergreen downgraded to Neutral from Buy at UBS
- Pactiv Evergreen downgraded to Sector Perform from Outperform at RBC Capital
- Pactiv Evergreen downgraded to Hold from Buy at Jefferies
- Pactiv Evergreen price target raised to $18 from $12 at Baird
- BofA moves to No Rating on Pactiv Evergreen after Novolex deal